Rituximab in the treatment of Pembrolizumab induced Myasthenia Gravis

1. Liewluck T, Kao JC, Mauermann ML. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies. J Immunother. 2018 May;41(4):208–11. Liewluck T Kao JC Mauermann ML . PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies . J Immunother. 2018 May ; 41 ( 4 ): 208 – 11 . 10.1097/CJI.000000000000019629200081 Search in Google Scholar

2. March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: A fatal case report. J Oncol Pharm Pr. 2018 Mar;24(2):146–9. March KL Samarin MJ Sodhi A Owens RE . Pembrolizumab-induced myasthenia gravis: A fatal case report . J Oncol Pharm Pr. 2018 Mar ; 24 ( 2 ): 146 – 9 . 10.1177/107815521668738928147928 Search in Google Scholar

3. Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019 Apr;24(4):435–43. Reynolds KL Guidon AC . Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature . Oncologist. 2019 Apr ; 24 ( 4 ): 435 – 43 . 10.1634/theoncologist.2018-0359645924030482825 Search in Google Scholar

4. Erkilinc B, Karagozlu E, Uludag B. S52. A case of myasthenia gravis related to use of pembrolizumab. Clin Neurophysiol. 2018 May 1;129:e161. Erkilinc B Karagozlu E Uludag B . S52. A case of myasthenia gravis related to use of pembrolizumab . Clin Neurophysiol. 2018 May 1 ; 129 : e161 . 10.1016/j.clinph.2018.04.412 Search in Google Scholar

5. Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018 Oct;6 (7):e00355. Hibino M Maeda K Horiuchi S Fukuda M Kondo T . Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer . Respirol Case Rep. 2018 Oct ; 6 ( 7 ): e00355 . 10.1002/rcr2.355607993230094028 Search in Google Scholar

6. Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY. Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer. J Clin Neurol. 2018 Jan;14(1):115–7. Huh SY Shin SH Kim MK Lee SY Son KH Shin HY . Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer . J Clin Neurol. 2018 Jan ; 14 ( 1 ): 115 – 7 . 10.3988/jcn.2018.14.1.115576524629629546 Search in Google Scholar

7. Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055– Kimura T Fukushima S Miyashita A Aoi J Jinnin M Kosaka T , et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab . Cancer Sci. 2016 ; 107 ( 7 ): 1055 – 10.1111/cas.12961494672227420474 Search in Google Scholar

8. Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Oncologist. 2018 Aug;23(8):874–8. Neilan TG Rothenberg ML Amiri-Kordestani L Sullivan RJ Steingart RM Gregory W , et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action . Oncologist. 2018 Aug ; 23 ( 8 ): 874 – 8 . 10.1634/theoncologist.2018-0157615618729802220 Search in Google Scholar

9. Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017 Sep 12;89(11):1127–34. Suzuki S Ishikawa N Konoeda F Seki N Fukushima S Takahashi K , et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan . Neurology. 2017 Sep 12 ; 89 ( 11 ): 1127 – 34 . 10.1212/WNL.000000000000435928821685 Search in Google Scholar

10. Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, et al. Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia GravisHeart and Skeletal Muscle Targeting in Myasthenia Gravis. JAMA Neurol. 2009;66(11):1334–8. Suzuki S Utsugisawa K Yoshikawa H Motomura M Matsubara S Yokoyama K , et al. Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia GravisHeart and Skeletal Muscle Targeting in Myasthenia Gravis . JAMA Neurol. 2009 ; 66 ( 11 ): 1334 – 8 . Search in Google Scholar

11. Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors. J Thorac Dis. 2018 May;10(Suppl 13):S1509-s1515. Yokoyama S Miyoshi H . Thymic tumors and immune checkpoint inhibitors . J Thorac Dis. 2018 May ; 10 ( Suppl 13 ): S1509 - s1515 . 10.21037/jtd.2017.10.157599450329951302 Search in Google Scholar

12. Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2018 Jun 15;Jco2017773184. Cho J Kim HS Ku BM Choi YL Cristescu R Han J , et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial . J Clin Oncol. 2018 Jun 15; Jco2017773184. 10.1200/JCO.2017.77.318429906252 Search in Google Scholar

13. Mygland Å, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, et al. Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. JAMA Neurol. 2000;57(4):527–31. Mygland Å Vincent A Newsom-Davis J Kaminski H Zorzato F Agius M , et al. Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia . JAMA Neurol. 2000 ; 57 ( 4 ): 527 – 31 . 10.1001/archneur.57.4.52710768628 Search in Google Scholar

14. Merveilleux du Vignaux C, Maury JM, Girard N. Novel Agents in the Treatment of Thymic Malignancies. Curr Treat Options Oncol. 2017 Aug 10;18(9):52. Merveilleux du Vignaux C Maury JM Girard N . Novel Agents in the Treatment of Thymic Malignancies . Curr Treat Options Oncol. 2017 Aug 10 ; 18 ( 9 ): 52 . 10.1007/s11864-017-0495-828795288 Search in Google Scholar

15. Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba I, et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017 Jun;30 (6):826–33. Weissferdt A Fujimoto J Kalhor N Rodriguez J Bassett R Wistuba I , et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms . Mod Pathol. 2017 Jun ; 30 ( 6 ): 826 – 33 . 10.1038/modpathol.2017.628281549 Search in Google Scholar

16. Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015 May;88 (2):154–9. Katsuya Y Fujita Y Horinouchi H Ohe Y Watanabe S Tsuta K . Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma . Lung Cancer. 2015 May ; 88 ( 2 ): 154 – 9 . 10.1016/j.lungcan.2015.03.00325799277 Search in Google Scholar

17. Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors. J Thorac Oncol. 2015 Mar 1;10 (3):500–8. Padda SK Riess JW Schwartz EJ Tian L Kohrt HE Neal JW , et al. Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors . J Thorac Oncol. 2015 Mar 1 ; 10 ( 3 ): 500 – 8 . 10.1097/JTO.0000000000000429472025725402569 Search in Google Scholar

18. Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019 Mar 1;266(3):699– 706. Topakian R Zimprich F Iglseder S Embacher N Guger M Stieglbauer K , et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria . J Neurol. 2019 Mar 1 ; 266 ( 3 ): 699 – 706 . 10.1007/s00415-019-09191-630649616 Search in Google Scholar

19. Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. Rituximab Crusz SM Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. Rituximab Search in Google Scholar